Friday, June 12, 2015

This Week in BioPharma: 6/8-6/12

Top news from the biopharmaceutical industry this week:

In the future, treatments tailored to patients: Cambridge biotechs such as Genzyme Corp. and Alnylam Pharmaceuticals Inc. are developing personalized treatments for rare genetic disorders like Gaucher and Fabry disease. Vertex Pharmaceuticals Inc. of Boston is turning out a portfolio of medicines that attack the life-threatening lung disease cystic fibrosis by targeting specific genetic mutations.

Getting to the red zone in biopharma R&D: For some time after the FDA put its new breakthrough therapy designation together for the industry, there was a good deal of back and forth among industry analysts over whether the BTD would make much of a difference. You don't hear much of that kind of carping much these days, and a new report from EP Vantage illustrates why.

Study: biopharma innovation outpaces tech overall: Innovation in the biotech and pharmaceutical industries outpaced the combined activity of 12 technology sectors between 2009 and last year, according to a report released today by Thomson Reuters.

The 25 most influential people in biopharma in 2015: A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business.

Alder Biopharmaceuticals' new drug promises migraine relief:  Shares of clinical-stage biopharmaceutical company Alder Biopharmaceuticals Inc. are up more than 100 percent from the lows they made in late April this year and are currently trading near their all-time highs.One of the main reasons for this surge has been the promising data released by company last month for its migraine treatment drug.

Cancer clinical trials expert to assist Regen BioPharma, Inc. in addressing FDA questions: The goals  of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success.

Merck Millipore develops compaction technology for biopharma: Merck Millipore, the life science business of Germany-based Merck, has developed a new technology that compacts dry powder cell culture media into granules, accelerating solubility and improving flowability and handling. The compacted media are, therefore, more convenient to use, allowing biopharmaceutical manufacturers to further optimize their upstream processes.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment